CERVOMED INC
CRVONASDAQTrading Snapshot
- Day Range
- $3.07 – $3.10
- 52-Week Range
- $2.13 – $11.25
- Volume
- $2.22B
- Avg Volume
- $2.53B
- Shares Outstanding
- 13.5M
- Next Earnings
- Sep 24, 2026
Fundamentals Snapshot
- Annual Revenue
- $2M
- Last Q Revenue
- $586,808
- P/E Ratio
- —
- P/S Ratio
- 18.1x
- EPS (TTM)
- $-3.27
- Dividend Yield
- —
Why Investors Own CRVO
- ✓High-growth profile — revenue up +55.9% YoY with expanding US Equity exposure.
- ✓Healthy economics — 68% gross margin and 15% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About CERVOMED INC
CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosses the blood–brain barrier and inhibits the enzyme p38a. Neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health, and slow or prevent disease progression. Neflamapimod is currently in clinical development for the treatment of dementia with Lewy bodies, non-fluent variant primary progressive aphasia, amyotrophic lateral sclerosis, and amyotrophic lateral sclerosis. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.
Otter Score Breakdown
ⓘAnalyst Ratings
ⓘLatest News & Updates
Canaccord Genuity Maintains Buy on CervoMed, Lowers Price Target to $18
Canaccord Genuity analyst Sumant Kulkarni maintains CervoMed (NASDAQ:CRVO) with a Buy and lowers the price target from $27 to $18.
CervoMed Q2 EPS $(0.64) Misses $(0.60) Estimate
CervoMed (NASDAQ:CRVO) reported quarterly losses of $(0.64) per share which missed the analyst consensus estimate of $(0.60) by 6.67 percent. This is a 8.57 percent increase over losses of $(0.70) per share from the
HC Wainwright & Co. Reiterates Buy on CervoMed, Maintains $25 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates CervoMed (NASDAQ:CRVO) with a Buy and maintains $25 price target.
CervoMed Announces New Clinical, Plasma Biomarker and Imaging Data at AAIC 2026 for Neflamapimod in the Treatment of Dementia with Lewy Bodies (DLB)
BOSTON, July 14, 2026 (GLOBE NEWSWIRE) -- CervoMed Announces New Clinical, Plasma Biomarker and Imaging Data at AAIC 2026 for Neflamapimod in the Treatment of Dementia with Lewy Bodies (DLB) New analyses of Phase 2b clinical trial reinforce treatment effect of neflamapimod observed relative to placebo in “pure” DLB and support selection of 50 mg TID for planned Phase 3 study in DLB Neflamapimod produced durable slowing of basal forebrain atrophy and increased basal forebrain connectivity relativ
CervoMed Presents New Insights Into Neflamapimod's Treatment Effects In Dementia with Lewy Bodies At The Alzheimer's Association International Conference 2026
New analyses of Phase 2b clinical trial reinforce treatment effect of neflamapimod observed relative to placebo in "pure" DLB and support selection of 50 mg TID for planned Phase 3 study in DLBNeflamapimod